|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
STA Standard
|
| ID number |
1136
|
Project Team
| Project lead |
Jeremy Powell |
Email enquiries
Stakeholders
| Companies sponsors |
Bristol-Myers Squibb |
| Others |
Department of Health |
| |
NHS England |
| Patient carer groups |
Bowel Cancer UK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
Amgen (panitumumab) CAU not signed (not participating) |
| |
Dr Reddy’s Laboratories (capecitabine) CAU not signed (not participating) |
| |
Glenmark Pharmaceuticals (capecitabine) CAU not signed (not participating) |
| |
Medac (folinic acid, fluorouracil, irinotecan, oxaliplatin) CAU not signed (not participating) |
| |
Merck (cetuximab) CAU not signed (not participating) |
| |
MSD (pembrolizumab) CAU signed - participating |
| |
Pfizer (irinotecan) CAU not signed (not participating) |
| |
Ranbaxy (irinotecan, oxaliplatin) CAU not signed (not participating) |
| |
Seacross Pharmaceuticals (irinotecan, oxaliplatin) CAU not signed (not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
British National Formulary |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
26 April 2024
|
In progress. Consultees have been invited to make submissions. |
|
26 April 2024
|
Invitation to participate |
|
30 November 2023
|
Please note that following on from advice received from the company this appraisal has been rescheduled. We now anticipate that the appraisal will begin during late-April 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late-June 2024. |
|
03 August 2023
|
Awaiting development. Please note that following on from information received from the company, this appraisal has now been scheduled back into the work programme. The timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-March 2024 when we will write to you about how you can get involved. |
|
31 January 2018
|
Suspended. The company have notified the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) that it wishes to withdraw its application for a marketing authorisation for nivolumab for this indication.
The NICE appraisal of nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] will therefore be suspended. |
|
16 November 2017
|
Committee meeting: 1 |
|
26 June 2017
|
In progress. Appraisal has started |
|
23 June 2017
|
Invitation to participate |
|
23 March 2017 - 13 April 2017
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
|
02 March 2017
|
Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual